Aminohippurate sodium is used as a diagnostic agent to measure kidney function.
aminohippurate sodium is to be given only by or under the direct supervision of a doctor.
Submit your review
difficulty with swallowing
large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
shortness of breath
tightness in the chest
unusual tiredness or weakness
Desire to defecate or urinate during or shortly after infusion
feeling of warmth
redness of the face, neck, arms, and occasionally, upper chest
redness of the skin
tingling of the skin
Clearance measurements using single injection techniques are generally inaccurate, particularly in the measurement of ERPF. For this reason, intravenous infusions at fixed rates are used to sustain the plasma PAH concentration at the desired level. To measure ERPF, the concentration of PAH in the plasma should be maintained at 2 mg per 100 mL, which can be achieved with a priming dose of 6 to 10 mg/kg and an infusion dose of 10 to 24 mg/min. As a research procedure for the measurement of TmPAH, the plasma level of PAH must be sufficient to saturate the capacity of the tubular secretory cells. Concentrations from 40 to 60 mg per 100 mL are usually necessary. Technical details of these tests may be found in Smith1; Wesson2; Bauer3; Pitts4; and Schnurr5. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit.